The proof of concept is the FDA-approved treatment for spinal muscular atrophy (SMA) where the drug Spinraza® modifies the existing SMN2 gene through the intrathecal administration of four loading doses of oligonucleotides in such a way that the SMN2 gene is produced in higher amounts. This evidence concerns the gene SMN2 and spinal muscular atrophy.